FDA authorizes extra dose of COVID-19 vaccine for immunocompromised people

Published



The Food and Drug Administration authorized extra doses of a COVID-19 vaccine for people with fragile immune systems who were not sufficiently protected after the first vaccination regimen.

“After a thorough review of the available data, the FDA determined that this small, vulnerable group may benefit from a third dose of the Pfizer-BioNTech or Moderna vaccines,” FDA Commissioner Janet Woodcock said.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.